IDXX · 8-K · 20260804PR090033

Product Launch and Transition

IDEXX LABORATORIES INC /DE · 2026-08-04 · Importance 49 · Surprise 66

IDEXX said innovation across its Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supported deeper customer adoption and higher diagnostic utilization. The IDEXX inVue Dx installed base surpassed 9,000 instruments after more than 1,600 placements during the quarter. CAG Diagnostics capital instrument revenue declined 19% reported and 20% organically because the quarter lapped the broad availability of IDEXX inVue Dx in the prior-year period, although current-year revenue benefited from the placements. Rapid assay revenue increased only 1% as the volume impact of Catalyst Pancreatic Lipase Test adoption eased while testing shifted across modalities.

Key facts